Antimicrobial resistance (AMR) is a growing threat, especially among Gram-negative bacteria. Emergence of resistance to β-lactam antibiotics - the most potent and prescribed class of antibiotic - is mainly due to the production of β-lactamase enzymes. Metallo-β-lactamase (MBL) enzymes are a particular concern and increasingly disseminated worldwide.^1,2
 

Infections caused by MBL-producing Gram-negative bacteria are often resistant to multiple drugs, leaving few obvious treatment options.¹
 

In 2020, WHO (World Health Organization) highlighted that lack of private investment and

innovation in the development of new antibiotics is undermining efforts to fight resistant

infections.³ Meanwhile, Gram-negative bacteria expressing MBLs continue to spread and evolve, with resistance to all β-lactam antibiotics.²
 

Without continued research and treatment breakthroughs, infections caused by Gram-negative bacteria expressing MBLs could soon become totally untreatable.¹

OUR PIPELINE PLEDGE
 

Unlike many large research-based pharmaceutical companies, Pfizer is still active in R&D,

focused on the treatment and prevention of infections caused by difficult-to-treat resistant

pathogens.⁴
 

We are committed to closing critical treatment gaps around the world, such as the treatment of Gram-negative bacterial and invasive fungal infections.⁴

Innovation and investment will help to halt the progress of antibacterial resistance. Coming

together as a team of stewardship champions could stop the spread for good.